

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



創美·CH'MEI
CHARMACY PHARMACEUTICAL CO., LTD.
 創美藥業股份有限公司
 (A joint stock limited liability company established in the People's Republic of China)
 (Stock Code: 2289)

**POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING
 HELD ON 17 April 2023**

References are made to the notice of the extraordinary general meeting of Charmacy Pharmaceutical Co., Ltd. (the “**Company**”) dated 27 March 2023 (the “**Notice of EGM**”) and the circular of the Company dated 27 March 2023 (the “**Circular**”). Terms used herein shall have the same meanings as those defined in the Circular unless the context requires otherwise.

POLL RESULTS OF THE EGM

The Board is pleased to announce that all the resolutions proposed as set out in the Notice of EGM were duly passed by the Shareholders by way of poll at the EGM.

The poll results in respect of all the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		Number of votes cast and percentage of total number of votes cast (%)		
		For	Against	Abstain
1.	THAT the framework loan agreement dated 2 March 2023 (the “ Framework Loan Agreement ”) entered into between the Company and Jiangxi Jiangzhong Pharmaceutical Commercial Operation Co., Ltd.* (江西江中醫藥商業運營有限責任公司) (“ Jiangzhong Yishang ”) in relation to the grant of loan facility not exceeding the maximum limit as authorised by the statutory approval authorities of both parties by Jiangzhong Yishang to the Group for a term of three years, the transactions contemplated thereunder and the proposed annual caps for the transactions contemplated thereunder, be and are hereby approved and confirmed; and	10,082,000 (100%)	0 (0%)	0 (0%)

2.	<p>THAT Mr. Yao Chuanglong be and is hereby authorised to (i) determine the relevant commercial terms arising from the Framework Loan Agreement, including but not limited to the interest rate of each individual loan agreements, the specific ratio of inventories of the Company and its subsidiaries as a collateral and the relevant collateral agreements, (ii) sign or execute such other documents or supplemental agreements or deeds on behalf of the Company, and (iii) do all such things and take all such actions as he/she may consider necessary or desirable for the purpose of giving effect to the Framework Loan Agreement and completing the transactions contemplated thereunder with such changes as he/she may consider necessary, desirable or expedient.</p>	<p>10,082,000 (100%)</p>	<p>0 (0%)</p>	<p>0 (0%)</p>
----	---	------------------------------	-------------------	-------------------

As more than 50% of the votes were cast in favour of each of the resolutions numbered 1 to 2, these resolutions were duly passed as ordinary resolutions of the Company.

Notes:

1. As at the date of the EGM, the total number of issued Shares was 108,000,000 Shares, which represented the total number of Shares entitling the holders to attend and vote on the proposed resolutions at the EGM.
2. Except for Jiangzhong Yishang, parties acting in concert with it and their respective associates (in respect of 84,656,500 Shares) who were required to abstain from voting in relation to the above resolutions, there were no Shares entitling the holders to attend and abstain from voting in favour of any of the proposed resolutions at the EGM pursuant to Rule 13.40 of the Listing Rules, nor were there any Shareholders who were required under the Listing Rules to abstain from voting at the EGM.
3. None of the Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the EGM.
4. For the above resolutions, the Shareholders, proxies or authorised representatives holding in aggregate of 10,082,000 Shares, representing approximately 9.34% of the total voting Shares, were present in person or by proxy at the EGM.
5. Pursuant to the Listing Rules, SHINEWING Certified Public Accountants (LLP), the auditors of the Company for the year 2022, was appointed as the scrutineer at the EGM for the purpose of vote-taking.
6. The attendance record of the Directors at the EGM was as follows:
Mr. Yao Chuanglong, and Ms. Zhang Hanzi attended in person;
Ms. Zheng Yuyan, Mr. Li Weisheng, Mr. Yan Jingbin, Ms. Fu Zheng, Mr. Zhou Tao and Mr. Guan Jian attended by electronic means; and
Mr. Wan Chi Wai Anthony was absent due to other engagements.

By order of the Board
Charmacy Pharmaceutical Co., Ltd.
Yao Chuanglong
Chairman

Shantou, the PRC, 17 April 2023

As at the date of this announcement, the executive Directors of the Company are Mr. Yao Chuanglong, Ms. Zheng Yuyan and Ms. Zhang Hanzi; the non-executive Directors of the Company are Mr. Li Weisheng, Mr. Yan Jingbin and Ms. Fu Zheng; and the independent non-executive Directors of the Company are Mr. Wan Chi Wai Anthony, Mr. Zhou Tao and Mr. Guan Jian (also known as Guan Suzhe).

** For identification purpose only*